Liraglutide Adolescent (12 to 17) Dosing

FDA Approval and Regulatory Background

The FDA approved liraglutide 3.0 mg for adolescents aged 12 and older with obesity in December 2020, making it the first GLP-1 receptor agonist cleared for pediatric weight management. Approval required a body weight of at least 60 kg and a BMI at or above the 95th percentile for age and sex 1.

How the Approval Differed From Adults

The adult indication for liraglutide 3.0 mg covers patients with a BMI of 30 kg/m² or above (or 27 kg/m² with a weight-related comorbidity). In adolescents, the FDA chose a percentile-based BMI cutoff because absolute BMI values shift as teens grow. The Endocrine Society 2023 pediatric obesity guidelines recommend pharmacotherapy for adolescents aged 12 and older when lifestyle modification alone has not produced sufficient weight reduction after three to six months.

Minimum Weight Requirement

The 60 kg threshold exists because the SCALE Teens trial enrolled only participants at or above that weight. Pharmacokinetic modeling showed that liraglutide exposure in adolescents weighing under 60 kg has not been characterized, so prescribing below that threshold falls outside the labeling 2.

Dose Escalation Schedule

Adolescent liraglutide dosing uses the same five-step weekly escalation as adult prescribing. Each step increases the daily dose by 0.6 mg. The schedule limits GI side effects (nausea, vomiting, diarrhea) that are most common during titration 1.

Week-by-Week Titration

| Week | Daily Dose | Injection Volume (6 mg/mL pen) | |------|-----------|-------------------------------| | 1 | 0.6 mg | 0.1 mL | | 2 | 1.2 mg | 0.2 mL | | 3 | 1.8 mg | 0.3 mL | | 4 | 2.4 mg | 0.4 mL | | 5+ | 3.0 mg | 0.5 mL |

If a patient cannot tolerate a dose increase, the prescribing label allows a one-week delay at the current dose before attempting the next step. Dose escalation should not skip steps. If the 3.0 mg dose remains intolerable after two attempts, discontinuation should be considered 2.

Timing and Injection Technique

Liraglutide is injected once daily at any time, independent of meals. The injection site should rotate among the abdomen, thigh, and upper arm. Adolescents or their caregivers should be trained on pen use, including priming with a new needle before each injection. The pen should be stored in a refrigerator (36 to 46 °F) before first use and at room temperature (up to 86 °F) for up to 30 days after.

SCALE Teens Trial Data

The SCALE Teens trial (NCT02918279) is the registration study supporting adolescent liraglutide approval. Published by Kelly et al. In the New England Journal of Medicine in 2020, the study enrolled 251 adolescents aged 12 to 17 with obesity across 32 sites in five countries 1.

Primary Efficacy Outcomes

Participants received liraglutide 3.0 mg or placebo for 56 weeks alongside lifestyle counseling. At week 56, the liraglutide group achieved a mean BMI reduction of 2.65% compared to a 1.64% BMI increase in the placebo group, yielding an estimated treatment difference of 4.29 percentage points (95% CI: 5.63 to 2.95; P<0.001).

A BMI reduction of 5% or more was reached by 43.3% of liraglutide-treated adolescents versus 18.7% on placebo. The 10% BMI reduction threshold was met by 26.1% in the liraglutide arm and 8.1% in the placebo arm 1.

Weight-Loss Trajectory

BMI reduction was progressive through week 56 with no plateau evident in the trial data. This contrasts with the adult SCALE Obesity trial (N=3,731), where body-weight loss with liraglutide 3.0 mg averaged 8.0% at 56 weeks compared to 2.6% with placebo 3. The smaller percentage change in adolescents partly reflects the fact that BMI in growing teens is a moving target: even maintaining weight during a growth spurt produces a meaningful BMI reduction.

Side-Effect Profile in Adolescents

Gastrointestinal events were the most frequent adverse effects. In SCALE Teens, nausea occurred in 42% of liraglutide-treated adolescents versus 14% on placebo, and vomiting in 26% versus 10%. Most GI symptoms appeared during the first eight weeks of treatment and decreased in frequency after full-dose attainment 1.

No cases of pancreatitis or medullary thyroid carcinoma were reported during the 56-week trial period. Lipase increases above three times the upper limit of normal occurred in 5.4% of liraglutide patients.

When to Discontinue: The 4% BMI Rule

The FDA label specifies a response assessment at 12 weeks on the maintenance dose of 3.0 mg. If an adolescent has not achieved at least a 4% reduction in BMI (or BMI z-score equivalent), the prescriber should consider discontinuing liraglutide 2.

Calculating the Response Window

The 12-week clock starts at week 5 of treatment (the first full week at 3.0 mg), placing the evaluation at approximately week 17 from treatment initiation. Clinicians should document the baseline BMI at initiation, not at the start of the dose escalation period.

What Happens After Stopping

In the SCALE Teens open-label extension, adolescents who discontinued liraglutide regained an average of 2.1 BMI units over the 26 weeks following cessation 1. This rebound mirrors the post-cessation weight regain documented in adult GLP-1 trials and supports the clinical understanding that obesity pharmacotherapy works during active treatment, not as a one-time course.

Growth and Puberty Monitoring

Adolescents between 12 and 17 are still growing. Liraglutide prescribing in this population requires attention to height velocity and pubertal development that adult prescribing does not.

Linear Growth Surveillance

In SCALE Teens, mean height increased by 1.8 cm in the liraglutide group and 2.1 cm in the placebo group over 56 weeks, a nonsignificant difference 1. Clinicians should plot height on CDC growth charts at every visit (minimum quarterly). A growth velocity below the 5th percentile for age and sex warrants a pause in treatment and endocrine evaluation. The AAP clinical practice guideline for pediatric obesity (2023) recommends tracking Tanner staging alongside weight endpoints.

Bone Health Considerations

Rapid weight loss during adolescence has been associated with reduced bone mineral accrual in observational studies 4. While SCALE Teens did not include DEXA scans, the AAP guideline recommends ensuring adequate calcium (1,300 mg/day) and vitamin D (600 IU/day) intake in any adolescent undergoing pharmacologic weight reduction.

Mental-Health Screening Requirements

The Saxenda label carries a warning about suicidal ideation and behavior based on post-marketing reports across GLP-1 receptor agonists. In SCALE Teens, suicidal ideation (assessed by the Columbia Suicide Severity Rating Scale, C-SSRS) was reported in 4 liraglutide-treated patients and 1 placebo patient 1.

Recommended Screening Schedule

The Endocrine Society 2023 guidelines recommend screening for depression, anxiety, eating disorders, and suicidal ideation at baseline and at every dose adjustment visit. A validated tool such as the PHQ-A (Patient Health Questionnaire for Adolescents) or C-SSRS should be documented. If new suicidal ideation emerges, liraglutide should be stopped and the patient referred for psychiatric evaluation.

Eating Disorder Risk

Adolescents with a history of anorexia nervosa, bulimia nervosa, or binge eating disorder were excluded from SCALE Teens. Prescribers should screen using the SCOFF questionnaire or similar tool before initiating liraglutide. GLP-1 agonists reduce appetite through central mechanisms, and their interaction with disordered eating behaviors has not been studied in controlled trials.

Drug Interactions and Contraindications in Adolescents

Liraglutide slows gastric emptying, which can alter the absorption of oral medications. This is clinically relevant for adolescents who may be taking oral contraceptives, methylphenidate, or other time-sensitive oral drugs 2.

Key Contraindications

Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In rodent studies, liraglutide caused thyroid C-cell tumors at exposures eight times the human dose, prompting a boxed warning 2. The clinical relevance of these rodent findings to humans remains uncertain.

Medications Requiring Timing Adjustment

Oral contraceptives should be taken at least one hour before the liraglutide injection or at a time when liraglutide-related gastric slowing has subsided (typically four or more hours post-injection). Adolescents on levothyroxine should have TSH monitored more frequently during the first three months. Insulin and sulfonylureas require dose reduction when used alongside liraglutide due to additive hypoglycemia risk, though this scenario applies primarily to the lower-dose (1.8 mg) indication for type 2 diabetes rather than the 3.0 mg obesity indication.

Liraglutide vs. Other GLP-1 Options for Adolescents

As of mid-2026, liraglutide 3.0 mg and semaglutide 2.4 mg (Wegovy) are the two GLP-1 receptor agonists with FDA clearance for adolescent weight management. The STEP TEENS trial (N=201) demonstrated a 16.1% reduction in BMI with semaglutide 2.4 mg weekly versus a 0.6% increase with placebo at 68 weeks 5.

Comparative Considerations

| Factor | Liraglutide 3.0 mg | Semaglutide 2.4 mg | |--------|-------------------|-------------------| | Dosing frequency | Once daily | Once weekly | | BMI reduction (teens) | 2.65% at 56 wk | 16.1% at 68 wk | | Injection volume | 0.5 mL at full dose | 0.5 to 1.0 mL depending on step | | Nausea incidence (teens) | 42% | 36% | | Generic availability (2026) | Yes (limited) | No |

The daily injection schedule of liraglutide is a disadvantage for adherence in teenagers compared to weekly semaglutide. Clinicians may choose liraglutide when cost is the primary barrier, since generic liraglutide has entered the market at lower price points 2.

Practical Prescribing Workflow

A step-by-step workflow for initiating liraglutide in a 12- to 17-year-old patient helps standardize care across primary care and pediatric endocrinology settings.

Pre-Prescribing Checklist

1. Confirm BMI at or above the 95th percentile for age and sex.
2. Verify body weight is 60 kg or above.
3. Document that lifestyle modification (nutrition counseling and physical activity) has been attempted for at least three to six months.
4. Screen for MEN 2 and personal or family history of medullary thyroid carcinoma.
5. Administer a baseline C-SSRS or PHQ-A.
6. Obtain baseline labs: fasting glucose, HbA1c, lipid panel, hepatic panel, lipase, calcitonin (if thyroid risk factors present), and TSH.

Follow-Up Schedule

• Week 1 through week 4 (titration): phone or telehealth check-in at each dose increase. Ask about nausea, vomiting, and injection-site reactions.
• Week 8: in-person visit. Record weight, height, BMI, vital signs, and C-SSRS.
• Week 17 (12 weeks at full dose): formal response evaluation. Recalculate BMI and compare to baseline. If BMI has not decreased by 4% or more, discuss discontinuation.
• Every 12 weeks thereafter: monitor weight, height, BMI percentile, growth velocity, Tanner stage, lipase, and mental-health screening.

Caregiver and Patient Education

Adolescents and their parents or guardians should understand that liraglutide is not a short-term medication. Weight regain after cessation is the expected outcome. Setting realistic goals (a 5 to 10% BMI reduction over the first year, with a focus on metabolic health markers rather than appearance) may reduce treatment dropout. Pen training should include hands-on practice with a demonstration device before the first injection.

Special Populations Within the 12 to 17 Range

Adolescents With Type 2 Diabetes

Liraglutide is separately approved at doses up to 1.8 mg once daily for type 2 diabetes in adults. In adolescents with both obesity and type 2 diabetes, the higher 3.0 mg dose is used for the weight-management indication. Combining liraglutide with metformin is common practice; the ADA Standards of Care (2024) list liraglutide as a second-line agent for pediatric type 2 diabetes when metformin alone does not achieve glycemic targets.

Adolescents on Psychotropic Medications

Second-generation antipsychotics (olanzapine, risperidone, quetiapine) frequently cause weight gain in adolescents. Small open-label studies suggest GLP-1 agonists may partially offset antipsychotic-associated weight gain 6. Prescribers should coordinate with the treating psychiatrist before adding liraglutide, given the overlapping GI side effects and the need for close mental-health monitoring.

Post-Bariatric Adolescents

Liraglutide has not been studied in adolescents who have previously undergone bariatric surgery. Altered GI anatomy after sleeve gastrectomy or Roux-en-Y gastric bypass changes drug absorption and GLP-1 physiology. Use in this population should be considered investigational.